Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Forschungsstudie an Kindern, die klein geboren wurden und klein blieben. Die Behandlung erfolgt mit Somapacitan einmal wöchentlich im Vergleich zu Norditropin® einmal täglich

5. Oktober 2026 aktualisiert von: Novo Nordisk A/S

Eine Dosisfindungsstudie zur Bewertung der Wirkung und Sicherheit einer einmal wöchentlichen Behandlung mit Somapacitan im Vergleich zur täglichen Behandlung mit Norditropin® bei kleinwüchsigen Kindern, die für das Gestationsalter klein geboren wurden und kein aufholendes Wachstum im Alter von 2 Jahren oder älter haben

The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).

Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once every week or once every day.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Tatsächlich)

62

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Algiers, Algerien, 16000
        • CHU Bab El Oued Pediatrics Dept
      • Algiers, Algerien, 16000
        • Endo and Diab Dept El Oued
      • Constantine, Algerien, 25000
        • endocrino-diabetology department, Hospital IBN BADIS.
      • Copenhagen Ø, Dänemark, 2100
        • Rigshospitalet Klinik for Vækst og Reproduktion Afsnit 5064
      • Tallinn, Estland, 13419
        • Tallinn Children's Hospital
      • Tartu, Estland, 50406
        • Tartu University Hospital Children's Clinic
      • Angers, Frankreich, 49100
        • Centre Hospitalier Universitaire D'Angers-2
      • Le Kremlin-Bicêtre, Frankreich, 94270
        • AP-HP-HOPITAL DE BICETRE_Service d'Endocrinologie pédiatrique
      • Marseille, Frankreich, 13005
        • Assistance Publique Hopitaux de Marseille-Hopital de La Timone-2
      • Marseille Cédex 05, Frankreich, 13385
        • Hopital de La Timone
      • Paris, Frankreich, 75015
        • Ap-Hp-Hopital Necker
      • Paris, Frankreich, 75015
        • Hôpital Necker
      • Toulouse, Frankreich, 31059
        • HOPITAL DES ENFANTS-HOPITAL PAULE DE VIGUIER - Pharmacie
    • Kerala
      • Kochi, Kerala, Indien, 682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Maharashtra
      • Pune, Maharashtra, Indien, 411001
        • Jehangir Clinical Development Centre
    • New Delhi
      • New Dehli, New Delhi, Indien, 110029
        • All India Institute of Medical Sciences
      • Dublin, Irland, D12 N512
        • CHI Crumlin Dept of Endocrinology
      • Haifa, Israel, 31096
        • Rambam MC - Department of Pediatrics A
      • Kfar Saba, Israel, 44281
        • Meir MC - Department of Paediatrics
      • Petah Tikva, Israel, 49202
        • Schneider MC - Endrocrinology and Diabetes
      • Florence, Italien, 50139
        • IRCCS Meyer Firenze
      • Genova, Italien, 16147
        • Ospedale Pediatrico Gaslini
      • Milan, Italien, 20122
        • Ospedale Maggiore Policlinico UO Endocrinologia Diabetolgia
      • Roma, Italien, 00165
        • Ospedale Pediatrico Bambino Gesu
      • Fukuoka, Japan, 830-0011
        • Kurume University Hospital, Pediatrics
      • Fukuoka-shi, Fukuoka, Japan, 813-0017
        • Fukuoka Children's Hospital_Endocrinology and Metabolism
      • Fukuoka-shi, Fukuoka, Japan, 813-0017
        • Fukuoka Children's Hospital
      • Fukuyama-shi, Hiroshima, Japan, 721-8511
        • Fukuyama City Hospital_Department of Pediatrics
      • Kobe-shi, Hyogo, Japan, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital Dept. Metab & endo
      • Kobe-shi, Hyogo, Japan, 650-0047
        • Hyogo Prefectual Kobe Children's Hospital_Metab & endo
      • Kyoto, Japan, 602-8566
        • Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics
      • Nara-shi, Nara, Japan, 630-8581
        • Nara Prefecture General Medical Center_ Nara-shi, Nara
      • Nara-shi, Nara, Japan, 630-8581
        • Nara Prefecture General Medical Center_Pediatric
      • Niigata-shi, Niigata, Japan, 951 8520
        • Niigata University Medical & Dental Hospital_Pediatrics
      • Osaka, Japan, 534-0021
        • Osaka City General Hospital, Pediatric Endocrinology and Me
      • Osaka, Japan, 594-1101
        • Osaka Women's and Children's Hospital
      • Saitama-shi, Saitama, Japan, 330-8777
        • Saitama Children's Medical Center, Endocrinorogy&Metabolism
      • Tokyo, Japan, 157 8535
        • National Center for Child Health and Dev, Endo and Metabo
      • Tokyo, Japan, 113-8519
        • Institute of Science Tokyo Hospital
      • Tokyo, Japan, 113-8519
        • Institute of Science Tokyo Hospital_Pediatrics
      • Tokyo, Japan, 157 8535
        • National Center for Child Health and Development_Endo and Metabo
      • Tokyo, Japan, 160-8582
        • Keio University Hospital_Pediatrics
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2B7
        • Stollery Children's Hospital
      • Riga, Lettland, 1004
        • Children's Clinical University Hospital
      • Bergen, Norwegen, 5021
        • Haukeland Universitetssykehus, Barneklinikken
      • Szczecin, Polen, 71-252
        • SPSK nr 1 im Prof. T Sokolowskiego
      • Warsaw, Polen, 04-730
        • Instytut ''Pomnik - Centrum Zdrowia Dziecka''
      • Izhevsk, Russland, 426009
        • Republic Children's Hospital of Ministry of Health of Udmurt
      • Moscow, Russland, 119435
        • Setchenov First Moscow State Medical University
      • Moscow, Russland, 125373
        • RMAPE
      • Novosibirsk, Russland, 630048
        • Children's clinical city hospital #1
      • Rostov-on-Don, Russland, 344013
        • FSBEI of Higher Education "Rostov State Medical University"
      • Saint Petersburg, Russland, 191144
        • SPSBHI City Children out-patient clinic #44
      • Samara, Russland, 443079
        • Samara Regional Children Clinical Hospital n.a. N.N. Ivanova
      • Tomsk, Russland, 634050
        • Siberian State Medical University
      • Bern, Schweiz, 3010
        • Med. Kinder- und Poliklinik
      • Zurich, Schweiz, 8032
        • Kinderspital Endokrinologie, Zürich
      • Belgrade, Serbien, 11000
        • University Children's Hospital Tirsova
      • Belgrade, Serbien, 11070
        • Institute for Mother and Child Health Care of Serbia
      • Kragujevac, Serbien, 34000
        • University Clinical Centre Kragujevac
      • Niš, Serbien, 18 000
        • Clinical Center in Nis
      • Novi Sad, Serbien, 21000
        • Institute for Health Care of Children and Adolescents
      • Esplugues Llobregat(Barcelona), Spanien, 08950
        • Hospital Sant Joan de Déu
      • Santiago de Compostela, Spanien, 15706
        • Hospital Clínico de Santiago de Compostela
      • Bangkok, Thailand, 10330
        • King Chulalongkorn Memorial hospital-Ped-Endocrinology
      • Bangkok, Thailand, 10330
        • King Chulalongkorn Memorial hospital_Ped-Endocrinology
      • Bangkok, Thailand, 10400
        • Phramongkutklao Hospital_Ped-Endo_Pediatrics
      • Dnipro, Ukraine, 49100
        • Dnipropetrovsk Regional Children's Clinical Hospital - Endocrinology department
      • Kharkiv, Ukraine, 61093
        • Kharkiv Regional Children's Clinical Hospital - Endocrinological department
      • Kyiv, Ukraine, 04114
        • Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
      • Budapest, Ungarn, 1023
        • Észak-Közép-budai Centrum, Szent János Kórház és Szakrendelő
      • Szeged, Ungarn, 6720
        • Szegedi Tudományegyetem Gyermekgyógyászati Klinika
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35233
        • Univ of AL at Birmingham_BRM
    • California
      • Orange, California, Vereinigte Staaten, 92868
        • Children's Hosp Of Orange
    • Idaho
      • Boise, Idaho, Vereinigte Staaten, 83712
        • St. Luke's Children's Endo
    • Minnesota
      • Minneapolis, Minnesota, Vereinigte Staaten, 55454
        • Univ of Minnesota M.C.H.
      • Saint Paul, Minnesota, Vereinigte Staaten, 55102
        • Children's Minnesota
    • New Jersey
      • Morristown, New Jersey, Vereinigte Staaten, 07962
        • Goryeb Children's Hospital
      • New Brunswick, New Jersey, Vereinigte Staaten, 08901
        • Rutgers-Rwjms
    • New York
      • Garden City, New York, Vereinigte Staaten, 11530
        • NYU Langone Hospital-LI
      • Mineola, New York, Vereinigte Staaten, 11501
        • NYU Langone Hospital-LI
      • New York, New York, Vereinigte Staaten, 10029
        • Icahn Sch of Med-Mt Sinai Hosp
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45229
        • CCHMC_Cinc
    • Oklahoma
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
        • Univ Oklahoma Sci Ctr OK City
    • Texas
      • Fort Worth, Texas, Vereinigte Staaten, 76104
        • Cook Children's Hospital-Hematology-Oncology
    • Washington
      • Tacoma, Washington, Vereinigte Staaten, 98405
        • MultiCare Inst for Res & Innov
      • Hull, Vereinigtes Königreich, HU3 2JZ
        • Hull Royal Infirmary
      • Liverpool, Vereinigtes Königreich, L12 2AP
        • Alder Hey Children's Hospital
      • London, Vereinigtes Königreich, E1 1BB
        • Royal London Hospital_London
      • Manchester, Vereinigtes Königreich, M13 9WL
        • Royal Manchester Children's Hospital
      • Graz, Österreich, 8036
        • Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie
      • Salzburg, Österreich, A 5020
        • LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde
      • Sankt Pölten, Österreich, 3100
        • LKH St. Poelten, Kinder-und Jugendheilkunde
      • Vöcklabruck, Österreich, 4840
        • Salzkammergut-Klinikum Vöcklabruck
    • Upper Austria
      • Linz, Upper Austria, Österreich, 4020
        • Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

2 Jahre bis 11 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Pre-pubertal children, boys:

    1. age between 2.5 and 11.0 years at screening.
    2. testes volume below 4 ml.
  • Pre-pubertal children, girls:

    1. age between 2.5 and 10.0 years at screening.
    2. Tanner stage 1 for breast development (no palpable glandular breast tissue).
  • Born small for gestational age (birth length and/or weight below -2 standard deviation scores) (according to national standards).

  • Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and gender at screening according to the standards of Centers for Disease Control and Prevention at screening.

  • Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and gender according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.

  • No prior exposure to growth hormone therapy or Insulin-like Growth Factor-I (IGF-I) treatment.

Exclusion Criteria:

  • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements.
  • Children with hormonal deficiencies including suspected or confirmed growth hormone deficiency according to local practise.
  • Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
  • Children requiring inhaled glucocorticoid therapy at a dose of greater than 400 μg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening.
  • Concomitant administration of other treatments that may have an effect on growth, e.g but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder.
  • Diagnosis of attention deficit hyperactivity disorder.
  • Prior history or presence of malignancy including intracranial tumours.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Somapacitan 0.24 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Experimental: Somapacitan 0.20 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Experimental: Somapacitan 0.16 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

Aktiver Komparator: Norditropin® 0.035 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

Aktiver Komparator: Norditropin® 0.067 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Height Velocity
Zeitfenster: Baseline (week 0); week 26

Height velocity (HV) was derived from height measurements taken at baseline (week 0) and week 26 visit as: HV = (height at 26 weeks visit - height at baseline)/(time from baseline to 26 weeks visit in years). The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Ratio of Bone Age Versus Chronological Age
Zeitfenster: Baseline (week 0); week 52

Change in ratio of bone age (years) versus chronological age (years) from baseline (week 0) to week 52 is presented. X-rays of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. X-ray images were sent to a central imaging laboratory for evaluation. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 52 or last trial contact, whichever came first.

Baseline (week 0); week 52
Change in Height Standard Deviation Score (HSDS)
Zeitfenster: Baseline (week 0); week 26

Change in HSDS from baseline (week 0) to week 26 is presented. HSDS was derived using Centre for Disease Control and Prevention (CDC) standards. HSDS = [(height/population median)^skewness - 1]/(skewness * population standard deviation) where skewness, median and standard deviation is given by a reference growth table for the corresponding chronological age. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Height Velocity Standard Deviation Score (HVSDS)
Zeitfenster: Baseline (week 0); week 26

Change in HVSDS from baseline (week 0) to week 26 is presented. HVSDS was derived using Prader standards. HV SDS was calculated using the formula: HV SDS = (height velocity - mean)/standard deviation (SD), where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HVSDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height velocity for a child with the same age and gender. Positive value in change from baseline in HVSDS indicated that HVSDS was better than baseline HVSDS. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Fasting Plasma Glucose
Zeitfenster: Baseline (week 0); week 26

Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Steady State Beta Cell Function (HOMA-B)
Zeitfenster: Baseline (week 0); week 26

Change in HOMA-B from baseline (week 0) to week 26 is presented. HOMA-B is a measure of the beta cell function and was calculated as follows: HOMA-B = (20 * fasting insulin (picomoles per liter [pmol/L]) * 1/6(microunit per milliliter [µU/mL]))/ FPG(mmol/L)-3.5). HOMA-beta score ranges from minus infinity to infinity (no limits). Higher score means better beta-cell function for HOMA-beta. Negative change from baseline (week 0) in HOMA-B indicated a worse outcome. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Zeitfenster: Baseline (week 0); week 26

Change in HOMA-IR from baseline (week 0) to week 26 is presented. Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body. HOMA-IR is calculated using a participant's fasting plasma insulin and glucose levels. HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5. HOMA-IR scores are classified as follows: less than 1.0: considered insulin sensitive, 0.5-1.4: considered healthy, above 1.8: considered early insulin resistance; above 2.7 is considered significant insulin resistance. HOMA-IR score ranges from 0-infinity (no upper limit). Higher the score, higher the level of insulin resistance. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Glycated Haemoglobin (HbA1c)
Zeitfenster: Baseline (week 0); week 26

Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS)
Zeitfenster: Baseline (week 0); week 26

Change in IGF-I SDS from baseline (week 0) to week 26 is presented. IGF-I SDS was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. Positive value in change from baseline in IGF-I SDS indicated that IGF-I SDS was higher than baseline IGF-I SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) SDS
Zeitfenster: Baseline (week 0); week 26

Change in IGFBP-3 SDS from baseline (week 0) to week 26 is presented. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. Positive value in change from baseline in IGFBP-3 SDS indicated that IGFBP-3 SDS was higher than baseline IGFBP-3 SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Clinical Reporting Anchor and Disclosure 1452, Novo Nordisk A/S

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

4. Juli 2019

Primärer Abschluss (Tatsächlich)

5. Mai 2021

Studienabschluss (Geschätzt)

23. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

15. März 2019

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

15. März 2019

Zuerst gepostet (Tatsächlich)

18. März 2019

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NN8640-4245
  • 2018 (US NIH Stipendium/Vertrag)
  • U1111-1207-9741 (Andere Kennung: World Health Organization (WHO))
  • 2018-000232-10 (EudraCT-Nummer)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren